Alnylam (Cambridge, MA) |
RNAi |
Influenza, RSV |
Phase 2 |
Argos (Durham, NC) |
Personalized immunotherapy |
HIV |
Phase 1/2 |
AVI Biopharma (Portland, OR) |
Antisense (Neugene) |
HCV |
Phase 1/2 |
Benitec Melbourne, Australia |
Cell-based therapy/triple RNAi |
HIV |
Phase 1 |
CytoDyn (Santa Fe, NM) |
mAb |
HIV |
Phase 1/2 |
Crucell (Leiden, the Netherlands) |
Antibody cocktail |
Rabies |
Phase 1 |
Dynavax (Berkeley, CA) |
TLR9 agonist (Heplisav) |
HBV |
Phase 3 |
Enzo Therapeutics (New York, NY) |
Antisense gene therapy |
HIV |
Phase 1/2 |
Human Genome Sciences (Rockville, MD) |
Modified interferon (Albuferon); mAb blocks CCR5 |
HCV HIV |
Phase 3 Phase 1 |
Idera (Cambridge MA) |
Oligonucleotide-based TLR9 agonist |
HCV |
Phase 1 |
Implicit Bioscience (Seattle, WA; Brisbane, Australia) |
Peptide immunomodulators |
HCV, influenza |
Phase 2 |
MacroGenics (Rockville, MD) |
mAb blocks CCR5 |
West Nile virus |
Phase 1 |
MedImmune (Rockville, MD) |
mAb (Numax, optimized Synagis) |
RSV |
Phase 3 completed (high-risk children); phase 1 (adults) |
NexBio (San Diego, CA) |
Recombinant sialidase |
Influenza |
Phase 1 |
Nucleonics (Horsham, PA) |
RNAi |
HBV |
Phase 1 |
Panacos (Watertown, MA) |
Maturation inhibitors (bevirimat) |
HIV |
Phase 2 |
Polymun Scientific (Vienna, Austria) |
mAb cocktail |
HIV |
Phase 2 |
Progenics (Tarrytown, NY) |
mAb blocks CCR5 |
HIV |
Phase 1b |
Protiva (Burnaby, BC, Canada) |
RNAi |
Ebola, Marburg |
Phase 1 |
Romark Laboratories (Tampa, FL) |
Mechanism unknown (nitazoxanide) |
HCV |
Phase 2 |
Schering-Plough (Kenilworth, NJ) |
Protease inhibitor (boceprevir) |
HCV |
Phase 2 |
SciClone Pharmaceuticals (Foster City, CA) |
Immunomodulator (Zadaxin, thymalfasin) |
HBV, HCV |
Marketed (HBV); phase 3 (HCV) |
SIGA Technologies (New York, NY) |
Viral particle blocker |
Smallpox, other orthopox |
Phase 1 |
United Biomedical (Hauppage, NY) |
Immunotherapeutic peptides |
HIV |
Phase 1 |
Vertex Pharmaceuticals (Cambridge, MA) |
Protease inhibitor (telaprevir) |
HCV |
Phase 2 |
VGX Pharmaceuticals (Blue Bell, PA) |
Steroid abortifacient (mifepristone) |
HIV, HCV |
Phase 2 |
VIRxSYS (Gaithersburg, MD) |
Gene-based immunotherapy |
HIV |
Phase 1 |